Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 47(1): 110-113, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34236726

RESUMEN

The management of pemphigus vulgaris (PV) is challenging. This study aimed to evaluate the immunomodulating effects of metformin on PV. The study was conducted in two phases: in the first phase, patients received routine first-line treatment (prednisolone plus azathioprine) for 2 months, then in the second phase, metformin was added to this regimen for another 2 months. After addition of metformin to the first-line medications, significant reductions were seen in serum IgG1 (reduced from 534.92 ± 134.83 mg/dL to 481.58 ± 130.46 mg/dL, P < 0.001), IgG4 (51.83 ± 27.26 mg/dL to 44.50 ± 26.05 mg/dL, P < 0.001) and interferon-γ (277.99 ± 108.71 pg/mL to 45.05 ± 17.080 pg/mL, P = 0.03) concentrations. The suppressant effect of metformin was greatest on IgG4 (coefficient of variation 1.28), the dominant subclass of IgG involved in PV. Metformin could have immunomodulating effects on PV with controlling effects on steroid complications.


Asunto(s)
Inmunoglobulina G/sangre , Interferón gamma/sangre , Metformina/uso terapéutico , Pénfigo/sangre , Pénfigo/tratamiento farmacológico , Adulto , Femenino , Humanos , Inmunoglobulina G/efectos de los fármacos , Interferón gamma/efectos de los fármacos , Masculino , Metformina/farmacología , Persona de Mediana Edad , Pénfigo/inmunología , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA